Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2016  |  Volume : 29  |  Issue : 4  |  Page : 826-834

Profiling of microRNA-122 in chronic hepatitis C


1 Department of Medical Microbiology and Immunology, National Liver Institute, Menoufia, Egypt
2 Department of Medical Microbiology and Immunology, Faculty of Medicine, Menoufia University, Menoufia, Egypt
3 Department of Biochemistry, National Liver Institute, Menoufia, Egypt

Correspondence Address:
Fatma O Khalil
Department of Medical Microbiology and Immunology, National Liver Institute, Menoufia University, Kafr Nafra Village, Berket El Sabae, Menoufia
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1110-2098.202489

Rights and Permissions

Objective The aim of this study was to assess the expression level of microRNA-122 (miRNA-122) in the serum as a diagnostic marker of liver injury in chronic hepatitis C, liver cirrhosis, and hepatocellular carcinoma (HCC). Background MicroRNAs are small RNA molecules including the liver specific, miRNA-122, which acts as a critical regulator of hepatic gene expression and an essential factor for hepatitis C virus (HCV) replication. Patients and methods A total of 112 participants who were divided into four groups were included in the study. Group I included 27 patients with chronic hepatitis C infection. Group II included 27 patients with HCC. Group III included 30 patients with chronic liver cirrhosis. Group IV included 18 healthy individuals without hepatitis C infection or any other disease who served as a control group. Liver function tests, α-fetoprotein, complete blood count, hepatitis C antibody, hepatitis B surface antigen, HCV-RNA using PCR, and detection of miRNA-122 in the serum using real-time PCR were carried out for all groups. Results The expression level of serum miRNA-122 displayed a significant fold increase in serum miRNA-122 in the HCV group compared with the other groups (P ≤ 0.0001). Patients with HCC showed a nonsignificantly higher expression level of miRNA-122 as compared with controls. miRNA-122 fold change at cutoff less than 1.64 could predict patients with HCC with 81.4% sensitivity and 48% specificity. Conclusion Measurements of serum miRNA-122 may be useful in the evaluation of HCV patients, by permitting with a serum test, the diagnosis of HCC with high predictivity and sensitivity.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed736    
    Printed0    
    Emailed0    
    PDF Downloaded101    
    Comments [Add]    

Recommend this journal